. 2021 Aug 2;36(1):1760–1782. doi: 10.1080/14756366.2021.1956488
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 2.
Rational design of new VEGFR-2 inhibitors.